Overview

Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of liposomal irinotecan plus bevacizumab in irinotecan-refractory metastatic colorectal cancer
Phase:
PHASE1
Details
Lead Sponsor:
Sun Yat-sen University
Treatments:
Bevacizumab
irinotecan sucrosofate